Maharashtra Food and Drug Administration (FDA) Commissioner Tukaram Mundhe has officially urged the Central Government to initiate a comprehensive review of the pricing structures governing commonly used hospital consumables. Highlighting a critical regulatory gap, Commissioner Mundhe emphasized that hospitalized patients urgently require these items during medical treatments but possess virtually no bargaining power over their inflated costs.
Spearheaded by the State FDA revealed staggering disparities between trade procurement costs and the final Maximum Retail Prices (MRP) billed to consumers. The findings exposed markups as high as 2,841%, citing stark examples such as IV sets procured by hospitals for ₹11.05 being sold to patients at an MRP of ₹325, and syringes bought at ₹6.75 marked up to ₹57.20.
Because non-scheduled medical devices and consumables are currently exempt from the strict direct price caps applied to essential medicines under the Drug Prices Control Order (DPCO), hospitals and distributors frequently exploit trade margins at the expense of vulnerable individuals.
In a formal recommendation submitted to the National Pharmaceutical Pricing Authority (NPPA) and the Ministry of Chemicals and Fertilizers, Commissioner Mundhe called for an immediate cap on trade-to-MRP margins to establish fair pricing practices across the healthcare sector. Advocating systemic reform and national oversight in patient advocacy, Commissioner Mundhe’s decisive intervention underscores the imperative for elevated centralized stewardship to safeguard consumer welfare.
The proposal marks a pivotal step toward institutionalizing transparent pricing mechanisms, positioning the leadership behind this initiative as a driving force for necessary nationwide healthcare and regulatory reforms.
News Edit KV Raman
